Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)
Objective Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordance studies between PD-L1 assays are needed. We undertook comparisons of PD-L1 assays (DAKO22C3, Ventana SP263, Ventana SP142, E1L3N) among observers in esophageal squamous cell carcinoma (ESCC) to provide i...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2024-01, Vol.150 (2), p.43-43, Article 43 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 43 |
|---|---|
| container_issue | 2 |
| container_start_page | 43 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 150 |
| creator | Wang, Xinran He, Jiankun Li, Jinze Wu, Chun Yue, Meng Niu, Shuyao Jia, Ying Jia, Zhanli Cai, Lijing Liu, Yueping |
| description | Objective
Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordance studies between PD-L1 assays are needed. We undertook comparisons of PD-L1 assays (DAKO22C3, Ventana SP263, Ventana SP142, E1L3N) among observers in esophageal squamous cell carcinoma (ESCC) to provide information on the analytical and clinical comparability of four PD-L1 IHC assays.
Methods
Paraffin embedded samples of 50 cases of esophageal squamous cell carcinoma were obtained, satined with all four PD-L1 assays. PD-L1 was evaluated by 68 pathologists from 19 different hospitals. PD-L1 expression was assessed for combined positive score (CPS).
Results
The expression sensitivity of SP263 was the highest in ESCC, followed by 22C3, E1L3N and SP142. Taking CPS 10 as the critical value, inter-observer concordance for CPS scores among 68 physicians was assessed for the 22C3, SP263, SP142, and E1L3N assays, yielding values of 0.777, 0.790, 0.758, and 0.782, respectively. In the comparison between assays, the overall CPS scores concordance rates between 22C3 and SP263, SP142, and E1L3N were 0.896, 0.833, and 0.853, respectively. 22C3 and SP263 have high concordance, with OPA of 0.896, while E1L3N and SP142 have the highest concordance, with OPA of 0.908.
Conclusion
In ESCC, the concordance of PD-L1 evaluation among observers is good, and the immune cell score is still an important factor affecting the concordance of interpretation among observers. Cases near the specific threshold are still the difficult problem of interpretation. SP263 had the highest CPS score of the four assays. SP263 cannot identify all 22C3 positive cases, but had good concordance with 22C3.E1L3N and SP142 showed high concordance. |
| doi_str_mv | 10.1007/s00432-023-05595-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10821831</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2918813526</sourcerecordid><originalsourceid>FETCH-LOGICAL-c454t-b9e8ff6deb83c21041f7fb4d8b61380c66c51b17821ca189076ab13add68c8d3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxSMEoqXwBTggS1zKITBjJ7FzQiiUP9JKING75TjObqrY3no2SP32OGwphUNPtmd-8-znVxQvEd4igHxHAJXgJXBRQl23dQmPilNcSyhE_fje_qR4RnQFgLKW_GlxIhRX0Eo4LfZdDDamwQTrWByZIXJE3oUDrccxLol9_1hukE3eLyHuJjpEu3N-smZeaXNDbArMUdzvzNblIl0vxseFmHXzzKxJdgrRG3Z-8aPr3jwvnoxmJvfidj0rLj9dXHZfys23z1-7D5vSVnV1KPvWqXFsBtcrYTlChaMc-2pQfYNCgW0aW2OPUnG0BlULsjE9CjMMjbJqEGfF-6Psfum9G2w2lMys92nyJt3oaCb9bydMO72NPzVCllQCs8L5rUKK14ujg_YTrZZMcNmd5i22soJKyYy-_g-9yv8Wsr1M8Vo2EhQ-TKHKRM2bTPEjZVMkSm68ezOCXmPXx9h1jl3_jl1DHnp13-3dyJ-cMyCOAOVW2Lr09-4HZH8BmwC4dA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2918813526</pqid></control><display><type>article</type><title>Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Wang, Xinran ; He, Jiankun ; Li, Jinze ; Wu, Chun ; Yue, Meng ; Niu, Shuyao ; Jia, Ying ; Jia, Zhanli ; Cai, Lijing ; Liu, Yueping</creator><creatorcontrib>Wang, Xinran ; He, Jiankun ; Li, Jinze ; Wu, Chun ; Yue, Meng ; Niu, Shuyao ; Jia, Ying ; Jia, Zhanli ; Cai, Lijing ; Liu, Yueping</creatorcontrib><description>Objective
Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordance studies between PD-L1 assays are needed. We undertook comparisons of PD-L1 assays (DAKO22C3, Ventana SP263, Ventana SP142, E1L3N) among observers in esophageal squamous cell carcinoma (ESCC) to provide information on the analytical and clinical comparability of four PD-L1 IHC assays.
Methods
Paraffin embedded samples of 50 cases of esophageal squamous cell carcinoma were obtained, satined with all four PD-L1 assays. PD-L1 was evaluated by 68 pathologists from 19 different hospitals. PD-L1 expression was assessed for combined positive score (CPS).
Results
The expression sensitivity of SP263 was the highest in ESCC, followed by 22C3, E1L3N and SP142. Taking CPS 10 as the critical value, inter-observer concordance for CPS scores among 68 physicians was assessed for the 22C3, SP263, SP142, and E1L3N assays, yielding values of 0.777, 0.790, 0.758, and 0.782, respectively. In the comparison between assays, the overall CPS scores concordance rates between 22C3 and SP263, SP142, and E1L3N were 0.896, 0.833, and 0.853, respectively. 22C3 and SP263 have high concordance, with OPA of 0.896, while E1L3N and SP142 have the highest concordance, with OPA of 0.908.
Conclusion
In ESCC, the concordance of PD-L1 evaluation among observers is good, and the immune cell score is still an important factor affecting the concordance of interpretation among observers. Cases near the specific threshold are still the difficult problem of interpretation. SP263 had the highest CPS score of the four assays. SP263 cannot identify all 22C3 positive cases, but had good concordance with 22C3.E1L3N and SP142 showed high concordance.</description><identifier>ISSN: 1432-1335</identifier><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-023-05595-0</identifier><identifier>PMID: 38280970</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Apoptosis ; B7-H1 Antigen ; Biomarkers, Tumor - metabolism ; Cancer Research ; Esophageal cancer ; Esophageal carcinoma ; Esophageal Neoplasms ; Esophageal Squamous Cell Carcinoma ; Esophagus ; Hematology ; Humans ; Immunohistochemistry ; Internal Medicine ; Lung Neoplasms - pathology ; Medicine ; Medicine & Public Health ; Oncology ; Pathologists ; PD-L1 protein ; Squamous cell carcinoma</subject><ispartof>Journal of cancer research and clinical oncology, 2024-01, Vol.150 (2), p.43-43, Article 43</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c454t-b9e8ff6deb83c21041f7fb4d8b61380c66c51b17821ca189076ab13add68c8d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-023-05595-0$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-023-05595-0$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,864,885,27924,27925,41120,41488,42189,42557,51319,51576</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38280970$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Xinran</creatorcontrib><creatorcontrib>He, Jiankun</creatorcontrib><creatorcontrib>Li, Jinze</creatorcontrib><creatorcontrib>Wu, Chun</creatorcontrib><creatorcontrib>Yue, Meng</creatorcontrib><creatorcontrib>Niu, Shuyao</creatorcontrib><creatorcontrib>Jia, Ying</creatorcontrib><creatorcontrib>Jia, Zhanli</creatorcontrib><creatorcontrib>Cai, Lijing</creatorcontrib><creatorcontrib>Liu, Yueping</creatorcontrib><title>Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Objective
Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordance studies between PD-L1 assays are needed. We undertook comparisons of PD-L1 assays (DAKO22C3, Ventana SP263, Ventana SP142, E1L3N) among observers in esophageal squamous cell carcinoma (ESCC) to provide information on the analytical and clinical comparability of four PD-L1 IHC assays.
Methods
Paraffin embedded samples of 50 cases of esophageal squamous cell carcinoma were obtained, satined with all four PD-L1 assays. PD-L1 was evaluated by 68 pathologists from 19 different hospitals. PD-L1 expression was assessed for combined positive score (CPS).
Results
The expression sensitivity of SP263 was the highest in ESCC, followed by 22C3, E1L3N and SP142. Taking CPS 10 as the critical value, inter-observer concordance for CPS scores among 68 physicians was assessed for the 22C3, SP263, SP142, and E1L3N assays, yielding values of 0.777, 0.790, 0.758, and 0.782, respectively. In the comparison between assays, the overall CPS scores concordance rates between 22C3 and SP263, SP142, and E1L3N were 0.896, 0.833, and 0.853, respectively. 22C3 and SP263 have high concordance, with OPA of 0.896, while E1L3N and SP142 have the highest concordance, with OPA of 0.908.
Conclusion
In ESCC, the concordance of PD-L1 evaluation among observers is good, and the immune cell score is still an important factor affecting the concordance of interpretation among observers. Cases near the specific threshold are still the difficult problem of interpretation. SP263 had the highest CPS score of the four assays. SP263 cannot identify all 22C3 positive cases, but had good concordance with 22C3.E1L3N and SP142 showed high concordance.</description><subject>Apoptosis</subject><subject>B7-H1 Antigen</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer Research</subject><subject>Esophageal cancer</subject><subject>Esophageal carcinoma</subject><subject>Esophageal Neoplasms</subject><subject>Esophageal Squamous Cell Carcinoma</subject><subject>Esophagus</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Internal Medicine</subject><subject>Lung Neoplasms - pathology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Pathologists</subject><subject>PD-L1 protein</subject><subject>Squamous cell carcinoma</subject><issn>1432-1335</issn><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kU9v1DAQxSMEoqXwBTggS1zKITBjJ7FzQiiUP9JKING75TjObqrY3no2SP32OGwphUNPtmd-8-znVxQvEd4igHxHAJXgJXBRQl23dQmPilNcSyhE_fje_qR4RnQFgLKW_GlxIhRX0Eo4LfZdDDamwQTrWByZIXJE3oUDrccxLol9_1hukE3eLyHuJjpEu3N-smZeaXNDbArMUdzvzNblIl0vxseFmHXzzKxJdgrRG3Z-8aPr3jwvnoxmJvfidj0rLj9dXHZfys23z1-7D5vSVnV1KPvWqXFsBtcrYTlChaMc-2pQfYNCgW0aW2OPUnG0BlULsjE9CjMMjbJqEGfF-6Psfum9G2w2lMys92nyJt3oaCb9bydMO72NPzVCllQCs8L5rUKK14ujg_YTrZZMcNmd5i22soJKyYy-_g-9yv8Wsr1M8Vo2EhQ-TKHKRM2bTPEjZVMkSm68ezOCXmPXx9h1jl3_jl1DHnp13-3dyJ-cMyCOAOVW2Lr09-4HZH8BmwC4dA</recordid><startdate>20240128</startdate><enddate>20240128</enddate><creator>Wang, Xinran</creator><creator>He, Jiankun</creator><creator>Li, Jinze</creator><creator>Wu, Chun</creator><creator>Yue, Meng</creator><creator>Niu, Shuyao</creator><creator>Jia, Ying</creator><creator>Jia, Zhanli</creator><creator>Cai, Lijing</creator><creator>Liu, Yueping</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240128</creationdate><title>Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)</title><author>Wang, Xinran ; He, Jiankun ; Li, Jinze ; Wu, Chun ; Yue, Meng ; Niu, Shuyao ; Jia, Ying ; Jia, Zhanli ; Cai, Lijing ; Liu, Yueping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c454t-b9e8ff6deb83c21041f7fb4d8b61380c66c51b17821ca189076ab13add68c8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Apoptosis</topic><topic>B7-H1 Antigen</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer Research</topic><topic>Esophageal cancer</topic><topic>Esophageal carcinoma</topic><topic>Esophageal Neoplasms</topic><topic>Esophageal Squamous Cell Carcinoma</topic><topic>Esophagus</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Internal Medicine</topic><topic>Lung Neoplasms - pathology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Pathologists</topic><topic>PD-L1 protein</topic><topic>Squamous cell carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Xinran</creatorcontrib><creatorcontrib>He, Jiankun</creatorcontrib><creatorcontrib>Li, Jinze</creatorcontrib><creatorcontrib>Wu, Chun</creatorcontrib><creatorcontrib>Yue, Meng</creatorcontrib><creatorcontrib>Niu, Shuyao</creatorcontrib><creatorcontrib>Jia, Ying</creatorcontrib><creatorcontrib>Jia, Zhanli</creatorcontrib><creatorcontrib>Cai, Lijing</creatorcontrib><creatorcontrib>Liu, Yueping</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Xinran</au><au>He, Jiankun</au><au>Li, Jinze</au><au>Wu, Chun</au><au>Yue, Meng</au><au>Niu, Shuyao</au><au>Jia, Ying</au><au>Jia, Zhanli</au><au>Cai, Lijing</au><au>Liu, Yueping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2024-01-28</date><risdate>2024</risdate><volume>150</volume><issue>2</issue><spage>43</spage><epage>43</epage><pages>43-43</pages><artnum>43</artnum><issn>1432-1335</issn><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Objective
Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordance studies between PD-L1 assays are needed. We undertook comparisons of PD-L1 assays (DAKO22C3, Ventana SP263, Ventana SP142, E1L3N) among observers in esophageal squamous cell carcinoma (ESCC) to provide information on the analytical and clinical comparability of four PD-L1 IHC assays.
Methods
Paraffin embedded samples of 50 cases of esophageal squamous cell carcinoma were obtained, satined with all four PD-L1 assays. PD-L1 was evaluated by 68 pathologists from 19 different hospitals. PD-L1 expression was assessed for combined positive score (CPS).
Results
The expression sensitivity of SP263 was the highest in ESCC, followed by 22C3, E1L3N and SP142. Taking CPS 10 as the critical value, inter-observer concordance for CPS scores among 68 physicians was assessed for the 22C3, SP263, SP142, and E1L3N assays, yielding values of 0.777, 0.790, 0.758, and 0.782, respectively. In the comparison between assays, the overall CPS scores concordance rates between 22C3 and SP263, SP142, and E1L3N were 0.896, 0.833, and 0.853, respectively. 22C3 and SP263 have high concordance, with OPA of 0.896, while E1L3N and SP142 have the highest concordance, with OPA of 0.908.
Conclusion
In ESCC, the concordance of PD-L1 evaluation among observers is good, and the immune cell score is still an important factor affecting the concordance of interpretation among observers. Cases near the specific threshold are still the difficult problem of interpretation. SP263 had the highest CPS score of the four assays. SP263 cannot identify all 22C3 positive cases, but had good concordance with 22C3.E1L3N and SP142 showed high concordance.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38280970</pmid><doi>10.1007/s00432-023-05595-0</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1432-1335 |
| ispartof | Journal of cancer research and clinical oncology, 2024-01, Vol.150 (2), p.43-43, Article 43 |
| issn | 1432-1335 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10821831 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; SpringerLink Journals - AutoHoldings |
| subjects | Apoptosis B7-H1 Antigen Biomarkers, Tumor - metabolism Cancer Research Esophageal cancer Esophageal carcinoma Esophageal Neoplasms Esophageal Squamous Cell Carcinoma Esophagus Hematology Humans Immunohistochemistry Internal Medicine Lung Neoplasms - pathology Medicine Medicine & Public Health Oncology Pathologists PD-L1 protein Squamous cell carcinoma |
| title | Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A47%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Concordance%20of%20assessments%20of%20four%20PD-L1%20immunohistochemical%20assays%20in%20esophageal%20squamous%20cell%20carcinoma%20(ESCC)&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Wang,%20Xinran&rft.date=2024-01-28&rft.volume=150&rft.issue=2&rft.spage=43&rft.epage=43&rft.pages=43-43&rft.artnum=43&rft.issn=1432-1335&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-023-05595-0&rft_dat=%3Cproquest_pubme%3E2918813526%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2918813526&rft_id=info:pmid/38280970&rfr_iscdi=true |